Clinical Trial Update: Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

View source ↗

Summary

A clinical trial entry indicates that a study evaluating peptide receptor radionuclide therapy for neuroendocrine tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumors

Snippet

Sponsor: Methodist Health System | Conditions: Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor | Status: RECRUITING